5-[2-(4-methoxy-phenyl)-ethyl]-2-(3-methyl-phenyl)-7-propoxy-oxazolo[5,4-d]pyrimidine | 1204758-31-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 5-[2-(4-methoxy-phenyl)-ethyl]-2-(3-methyl-phenyl)-7-propoxy-oxazolo[5,4-d]pyrimidine
• 英文别名: 5-[2-(4-Methoxyphenyl)ethyl]-2-(3-methylphenyl)-7-propoxy-[1,3]oxazolo[5,4-d]pyrimidine
• CAS: 1204758-31-5
• 化学式: C₂₄H₂₅N₃O₃
• 分子量: 403.481
• InChiKey: KMUJVWGQCZYAAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  70.3
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS<br/>[FR] OXAZOLOPYRIMIDINES COMME AGONISTES DU RÉCEPTEUR EDG-1
  申请人：SANOFI AVENTIS

  公开号：WO2010006704A1

  公开（公告）日：2010-01-21

  The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R1, R2 and R3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的恶唑并嘧啶化合物，其中A，R1，R2和R3的定义如权利要求所述。式I的化合物能够调节Edg-1受体的活性，特别是作为该受体的激动剂，并且可用于治疗例如动脉粥样硬化、心力衰竭或外周动脉闭塞性疾病等疾病。此外，本发明还涉及制备式I化合物的方法、它们的使用，特别是在药物中的活性成分，以及包含它们的药物组合物。
• OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS
  申请人：Kadereit Dieter

  公开号：US20110190490A1

  公开（公告）日：2011-08-04

  The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R 1 , R 2 and R 3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的噁唑嘧啶化合物，其中A、R1、R2和R3如权利要求所示。式I的化合物调节Edg-1受体的活性，特别是该受体的激动剂，并且可用于治疗动脉粥样硬化、心力衰竭或外周动脉闭塞性疾病等疾病。本发明还涉及制备式I的化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。
• Oxazolopyrimidines as Edg-1 receptor agonists
  申请人：SANOFI

  公开号：EP2583720A1

  公开（公告）日：2013-04-24

  The present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R1, R2 and R3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式 I 的噁唑嘧啶化合物、 其中A、R1、R2和R3的定义如权利要求所述。式 I 的化合物可调节 Edg-1 受体的活性，尤其是该受体的激动剂，可用于治疗动脉粥样硬化、心力衰竭或外周动脉闭塞症等疾病。本发明还涉及式 I 化合物的制备工艺、其用途（尤其是作为药物的活性成分）以及包含它们的药物组合物。
• US8735387B2
  申请人：——

  公开号：US8735387B2

  公开（公告）日：2014-05-27